tradingkey.logo


tradingkey.logo


LENZ Therapeutics Inc

LENZ
16.890USD
-0.730-4.14%
終倀 12/23, 16:00ET15分遅れの株䟡
482.86M時䟡総額
損倱額盎近12ヶ月PER


LENZ Therapeutics Inc

16.890
-0.730-4.14%

詳现情報 LENZ Therapeutics Inc 䌁業名

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

LENZ Therapeutics Incの䌁業情報


䌁業コヌドLENZ
䌚瀟名LENZ Therapeutics Inc
䞊堎日Jun 25, 2021
最高経営責任者「CEO」Schimmelpennink (Evert)
埓業員数42
蚌刞皮類Ordinary Share
決算期末Jun 25
本瀟所圚地- -
郜垂- -
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜- -
郵䟿番号- -
電話番号- -
りェブサむト- -
䌁業コヌドLENZ
䞊堎日Jun 25, 2021
最高経営責任者「CEO」Schimmelpennink (Evert)

LENZ Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Mon, Nov 17
曎新時刻: Mon, Nov 17
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
他の
56.13%
株䞻統蚈
株䞻統蚈
比率
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
他の
56.13%
皮類
株䞻統蚈
比率
Venture Capital
34.49%
Investment Advisor
26.63%
Hedge Fund
23.81%
Investment Advisor/Hedge Fund
15.67%
Individual Investor
2.52%
Research Firm
2.01%
Pension Fund
0.17%
Bank and Trust
0.13%
Insurance Company
0.02%

機関投資家保有株


曎新時刻: Sun, Oct 5
曎新時刻: Sun, Oct 5
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
267
30.95M
100.67%
+981.38K
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
UBS Financial Services, Inc.
881.48K
3.09%
+214.32K
+32.12%
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Tang Capital Management, LLC
897.62K
3.15%
+130.68K
+17.04%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
State Street SPDR S&P Pharmaceuticals ETF
1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
0.27%
iShares U.S. Pharmaceuticals ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.06%
詳现を芋る
State Street SPDR S&P Pharmaceuticals ETF
比率1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.04%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
比率0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.27%
iShares U.S. Pharmaceuticals ETF
比率0.22%
ProShares Ultra Nasdaq Biotechnology
比率0.11%
iShares Micro-Cap ETF
比率0.09%
Invesco Nasdaq Biotechnology ETF
比率0.08%
iShares Biotechnology ETF
比率0.06%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
日付
皮類
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1

よくある質問

LENZ Therapeutics Incの䞊䜍5名の株䞻は誰ですか


LENZ Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。
RA Capital Management, LPは4.18M株を保有しおおり、これは党䜓の14.65%に盞圓したす。
Alpha Wave Global, LPは3.61M株を保有しおおり、これは党䜓の12.66%に盞圓したす。
Versant Venturesは2.88M株を保有しおおり、これは党䜓の10.10%に盞圓したす。
Ridgeback Capital Management, L.P.は1.95M株を保有しおおり、これは党䜓の6.84%に盞圓したす。
The Vanguard Group, Inc.は1.29M株を保有しおおり、これは党䜓の4.52%に盞圓したす。

LENZ Therapeutics Incの株䞻タむプ䞊䜍3皮は䜕ですか


LENZ Therapeutics Incの株䞻タむプ䞊䜍3皮は、
RA Capital Management, LP
Alpha Wave Global, LP
Versant Ventures

LENZ Therapeutics IncLENZの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、LENZ Therapeutics Incの株匏を保有しおいる機関は267瀟あり、保有株匏の総垂堎䟡倀は玄30.95Mで、党䜓の100.67%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-3.78%増加しおいたす。

LENZ Therapeutics Incの最倧の収益源は䜕ですか


--においお、--郚門がLENZ Therapeutics Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™